Pure Global
NCT06357923

Study of the Evolution of the Expression of the LAMP-2 Protein During the Advance in Age

Study of the Evolution of the Expression of the LAMP-2 Protein During the Advance as Well as Variations and Allelic Mutations in the Main Genes Involved in the Occurrence of Age-related Myelodysplastic Syndromes
Centre Hospitalier Universitaire de Nice·ClinicalTrials.gov·diagnostic testNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Aging
Drug/Device/Intervention
dosage
Study type
Interventional
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Centre Hospitalier Universitaire de Nice
Location
Nice, France
Timeline & enrollment
Phase
N/A
Start date
May 01, 2024
End date
May 01, 2026
Enrollment
100 participants
Primary outcome

Expression level of LAMP2 (protein and isoform A and B mRNA)

Summary

Recruitment on the RAV pole in consultation or day hospital. Competitive recruitment of
 subjects 60 years of age respecting a male/female ratio = 1.

ICD-10 classifications
Alzheimer diseaseAgenesis and underdevelopment of noseAgenesis of lungAdult-onset Still diseaseChoroidal degeneration
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06357923
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06357923 through Pure Global AI's free database. This phase not specified trial is sponsored by Centre Hospitalier Universitaire de Nice and is currently Not yet recruiting. The study focuses on Aging. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.